作者: Paul H. Naylor , Marcelo B. Sztein , Saiji Wada , Scott Maurer , Daniel Holterman
DOI: 10.1016/0192-0561(91)90133-R
关键词:
摘要: Immunization with a synthetic HIV-1 p17 peptide analog (HGP-30; aa 85-115 of HIV p17), coupled to carrier protein (KLH, keyhole limpet hemocyanin) given alum as the adjuvant induces antibodies which cross-react both HGP-30 and clones cytotoxic helper T-cells recognize p17. Proliferation lymphocytes in response has been observed mice, HIV-infected individuals healthy HIV-seronegative volunteers vaccinated p17-based construct. Cytotoxic T-cell responses against EBV transformed, recombinant pulsed targets were using antigen-expanded PBLs from HGP-30-KLH immunized individuals. These results are consistent predictions that domain contains T- B-cell epitopes recognized by animals humans. In preclinical toxicology studies initial clinical trials humans construct (HGP-30-KLH/alum) shown be safe. This paper summarizes immunogenicity safety data for presents first Phase 1 trial.